Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai

Lung India

Volumn 31, Issue 4, 2014, Pages 336-341

  Udwadia, Zarir ^a   Moharil, Gautam ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

India; individualized regimens; multidrug resistant tuberculosis; private practitioners; private sector

Indexed keywords

AMINOGLYCOSIDE; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; SPARFLOXACIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTICLE; COUGHING; DESCRIPTIVE RESEARCH; FEMALE; FEVER; HEMOPTYSIS; HEPATITIS; HUMAN; HYPOTHYROIDISM; INDIA; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIVATE HOSPITAL; PROSPECTIVE STUDY; TERTIARY CARE CENTER; TREATMENT DURATION; VESTIBULAR DISORDER; VISUAL FIELD DEFECT;

EID: 84908473468     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.142101     Document Type: Article

References (29)

1. Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, et al. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: Retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 2013;18. pii: 20601.
2. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61.
3. World Health Organization Report 2013 (Global Tuberculosis Report, 2013). Available from: http://www.who.int/tb/publications/global-report/en. [Last accessed on 2014 May 27].
4. Dsouza DT, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, et al High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health 2009 9 211.
5. Bemer P, Palicova F, Rüsch-Gerdes S, Drugeon HB, Pfyffer GE. Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 2002;40:150-4.
6. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006;55:1176.
7. Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-Plus pilot experience in India: Results, constraints and issues. Int J Tuberc Lung Dis 2009;13;976-81.
8. Udwadia ZF, Pinto LM, Uplekar MW. Tuberculosis management by private practitioners in Mumbai, India: Has anything changed in two decades? PLoS One 2010;5:e12023.
9. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993;270:65-8.
10. Caminero JA, de March P. Statements of ATS, CDC, and IDSA on treatment of tuberculosis. Am J Respir Crit Care Med 2004;169:316-7.
11. World Health Organization. Treatment of tuberculosis: Guidelines for national programmes. 3 rd ed. WHO/CDS/TB/2003. 313. Geneva, Switzerland: WHO; 2003.
12. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
13. Moharil GK, Udwadia ZF. Treating extensively drug resistant tuberculosis (XDR-TB) in India. ERS Annual Congress 2008. Session 254.
14. Mohapatra PR. Fluoroquinolones in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004;170:920-1.
15. Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995;345:1148-50.
16. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009;13:79-83.
17. Kashyap S, Mohapatra PR. TB anywhere is TB everywhere. We must act now! Indian J Chest Dis Allied Sci 2007;49:197-8.
18. Chan ED, Lauren V, Strand MJ, Chan JF, Huynh ML, Goble M, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-9.
19. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669-83.
20. Fortn J, Martn-Dvila P, Navas E, Pérez-Elas MJ, Cobo J, Tato M, et al Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005 56 180-5
21. Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002;6:143-9.
22. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alćntara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-28.
23. Subhash HS, Ashwin I, Jesudason MV, Abharam OC, John G, Cherian AM, et al. Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: A retrospective study. Indian J Chest Dis Allied Sci 2003;45:97-103.
24. Thomas A, Ramachandran R, Rehaman F, Jaggarajamma K, Santha T, Selvakumar N, et al. Management of multi drug resistance tuberculosis in the field: Tuberculosis Research Centre experience. Indian J Tuberc 2007;54:117-24.
25. Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res 2011;133:529-34.
26. Isaakidis P, Paryani R, Khan S, Mansoor H, Manglani M, Valiyakath A, et al. Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India. PLoS One 2013;8:e68869.
27. Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, et al. DOTS-Plus for patients with multidrug-resistant tuberculosis in India: Early results after three years. Indian J Chest Dis Allied Sci 2007;49:75-9.
28. Dhingra VK, Rajpal S, Mittal A, Hanif M. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic. Indian J Tuberc 2008;55:15-21.
29. Jana PK, Das I, Sanyal D, Mandal K. The treatment outcome of multi drug resistant tuberculosis in a teaching hospital. Int Med J 2009;16:131-6.